ABIVAX Société Anonyme (ABVX.PA) was downgraded by Wall Street Zen from Hold to Sell on Saturday.
The clinical-stage biotech reported a quarterly loss of $1.71 per share, larger than analysts expected. Revenue was $1.37 million, exceeding expectations.
ABIVAX shares opened at $91.06, down 4%. The share price was below its 50-day and 200-day moving averages.
The broader analyst consensus remains Moderate Buy. The average price target is $156.69.
The company’s market capitalization is $7.95 billion.